Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864148 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 419
- Enrollment target
NCT01864148 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 419 participants.
The verdict
NCT01864148, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 419 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population pharmacokinetics of BIIB033 when used concurrently with Avonex.
Interventions
- OTHER Placebo
- DRUG Avonex
- DRUG BIIB033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864148
The ClinicalTrials.gov registry entry for NCT01864148 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01864148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01864148 about?
NCT01864148 is a clinical study titled "Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex". The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population pharmacokine...
What is the current status of trial NCT01864148?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 419 participants. The study started on 2013-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01864148?
The interventions under investigation include: Placebo (OTHER), Avonex (DRUG), BIIB033 (DRUG).
Who is sponsoring clinical trial NCT01864148?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.